Yingsi Yang
About Yingsi Yang
Yingsi Yang is the Associate Director of Biostatistics at Bristol Myers Squibb with extensive experience in the biopharmaceutical industry, having held senior roles at Five Prime Therapeutics, Jazz Pharmaceuticals, and Gilead Sciences.
Current Title and Position
Yingsi Yang currently holds the position of Associate Director, Biostatistics at Bristol Myers Squibb. In this role, Yang focuses on biostatistical analysis and support for various clinical trials and research initiatives within the company.
Previous Positions in Biostatistics
Before joining Bristol Myers Squibb, Yingsi Yang worked as Director, Biostatistics at Five Prime Therapeutics, Inc. from 2019 to 2021, where he specialized in biostatistical analysis for clinical trials. He also served as Senior Manager, Biostatistics at Jazz Pharmaceuticals from 2018 to 2019, contributing to the development of statistical methodologies for drug development. Earlier, Yang spent several years at Gilead Sciences in San Francisco Bay Area as Manager Biostatistics from 2017 to 2018 and Senior Biostatistician from 2013 to 2016, playing a crucial role in biostatistical support for regulatory submissions.
Academic Background and Early Career
Yingsi Yang has a strong academic background with a Doctor of Philosophy (Ph.D.) from The Hong Kong University of Science and Technology, obtained between 2008 and 2012. Prior to that, he studied at National Tsing Hua University from 2006 to 2007 and achieved a Bachelor's degree from Harbin Institute of Technology between 2004 and 2008. His early career includes a stint as a Postdoctoral Researcher at HKUST from 2012 to 2013 and work as a Research Assistant from 2008 to 2012. Yang's initial industry experience was gained through an internship at IBM in Beijing, China in 2007.
Experience in Biopharmaceutical Industry
Yingsi Yang has extensive experience in the biopharmaceutical industry. Over the years, he has held multiple senior roles in biostatistics across various companies. At Five Prime Therapeutics, Inc., he worked on biostatistical analysis for clinical trials. At Jazz Pharmaceuticals, he was instrumental in developing statistical methodologies for drug development. His tenure at Gilead Sciences involved significant contributions to regulatory submissions through biostatistical support, underscoring his expertise in both clinical and regulatory aspects of biostatistics.